Immunotherapy combo shows promise in rare kidney cancer trial
NCT ID NCT03274258
First seen Dec 18, 2025 · Last updated Jun 13, 2026 · Updated 22 times
Summary
This study tested two immunotherapy drugs, nivolumab and ipilimumab, in 10 people with a rare and aggressive kidney cancer called renal medullary carcinoma. The goal was to see if the combination could shrink tumors or stop them from growing. The trial was stopped early, but the results may still provide useful information for treating this difficult cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV RENAL CELL CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.